RE: Bullish Story for PXS - Current State24 Feb 2026 19:26
Competition? Fruitflow is a "Blue Ocean" product in China, entering an entirely uncontested market. Under SAMR protocols, once approved, the Healthy Blood Flow category is effectively locked to By-Health for a 5-year exclusivity period. Competitors would need to wait for this to expire before beginning a ~2-year clinical trial submission process, creating a 7-year barrier to entry.
Rather than spend millions on inferior alternatives, rivals are expected to simply purchase the "Gold Standard" through By-Health. This establishes a state-sanctioned monopoly on a new cardiovascular pillar.
By-Health is positioning Fruitflow as a platform ingredient for Healthy China 2030, targeting platelets, blood pressure, glucose management, and potentially the microbiome. While no one can predict the exact date, evidence shows the science has passed Technical Review and the first Blue Hat products have cleared Onsite Verification. We are now in the final Administrative Approval Phase. While some investors in China anticipate approval this week, others in the UK are rightfully cautious given their experience to date.
As for the timeframe: purely speculation; I believe the October production run of Fruitflow sent a batch to China for By-Health to do a small production run of Fruitflow-based products, and support their SAMR Onsite Verifications. Then the February production run will largely be heading to China. If this is true, they likely used a 3rd party company to fund/purchase the stock, then we purchase it from them as and when required. Large chunks of money will be made by PXS on completion of orders, so perhaps March/April.
People will certainly have their views about this, but that's where my thinking is. I may be completely wrong! Time will tell.
Sign In
Follow the stocks
